Publicis Adds Gilead to a Winning Streak That Is Starting to Look Like a Pattern

Publicis has won Gilead Sciences' US media account, adding one of the more valuable pharmaceutical assignments in the market to a new-business record that competitors have spent two years failing to interrupt.

Gilead is not a trophy for the logo alone. The company continues to see strong growth in its HIV portfolio, and pharmaceutical media is among the most technically demanding work in the industry: regulated claims, precise audience targeting, and a measurement burden that punishes agencies who treat health like packaged goods.

That is the terrain Publicis has been deliberately claiming. Its pitch for years has been data infrastructure first, creative charm second — a proposition that lands badly in a beauty review and extremely well in a category where the wrong impression served to the wrong audience is a compliance problem, not a wasted click.

For the rest of the holdco set, the loss compounds. Media reviews cluster, and incumbency in pharma has historically been sticky; when it moves, it tends to move in the same direction as the last three decisions.

The broader read: consolidation of marketing science is doing more for new business right now than any reel. Clients are buying plumbing, and Publicis keeps showing up with the better pipes.